Regeneron Pharmaceuticals is a biotechnology company. Co.'s products include: EYLEA, which is designed for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity; Dupixent, which is designed for the treatment of atopic dermatitis, asthma, rhinosinusitis with nasal polyposis, eosinophilic esophagitis (in adults and adolescents) and prurigo nodularis; and Libtayo, which is designed for the treatment of metastatic or locally advanced first-line non-small cell lung cancer and metastatic or recurrent second-line cervical cancer. When considering the Regeneron Pharmaceuticals, Inc. stock dividend history, we have taken known splits into account, such that the REGN dividend history is presented on a split-adjusted ("apples to apples") basis. Regeneron Pharmaceuticals, Inc. dividend history is presented both in graphical/chart form, and as a REGN dividend history data table along the right-hand column.
|
REGN Stock Dividend HistoryThe REGN dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable REGN historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the REGN dividend history record. Also see the REGN stock dividend history data table along the right-hand column below. |
|
|
Buy (3.44 out of 4) 57th percentile
(ranked higher than approx. 57% of all stocks covered)
Analysts' Target Price: REGN Forecast Based on data provided by Zacks Investment Research via Quandl.com |